UNAIDS HIV Drug Access Initiative: Providing Wider Access to HIV-related Drugs in Developing Countries, Pilot Phase

In a significant improvement for patient care, a standard patient medical record has been established and each clinic now maintains centralized records for patients. Prior to the development of this system, patients were given a hand-written record after each physician visit and were responsible for keeping their own records and bringing them to the doctor at each visit. As a result, patient medical records were not always reliable. CSte d'Ivoire With a population approaching 13 million and, by 1998, an HIV-infected population of over 800,000, C6te d'Ivoire was, like Uganda, chosen for the pilot programme with the full commitment of its government. The Minister of Public Health later announced that the equivalent of US$ 1 million would be made available, in the form of a Solidarity Fund, to help the poorest categories of patient to meet the cost of treatment. The "Fonds de Solidarit6 Th6rapeutique International" has also provided US$1.3 million for the next two years to provide long-term antiretroviral treatment to HIV pregnant women who are symptomatic or at the stage of immune depression as well as to help people on double therapy to reach triple therapy. * More than 190 physicians, other health care workers, and social workers have been trained in three large 5-day workshops. The sessions included training on the use of ARVs, drugs for opportunistic infections and psychosocial counselling. / Approximately 650 patients are receiving drugs through the Initiative. This number is expected to increase rapidly as the rebate schemes of the National Solidarity Fund and of the International Therapeutic Solidarity Fund become operational. * Participating facilities include 8 referral centres and 4 follow-up centres in Abidjan, and 4 follow-up centres outside the city (Bouak6, Korhogo, Daloa and Bondoukou). Plans are underway to upgrade the follow-up centres to referral centres through the expansion of laboratory facilities. * Each referral centre employs at a minimum a medical officer, several nurses, a person responsible for the delivery of ARV and a social assistant. Follow-up centres are provided with drugs for opportunistic infections. Advisory Board A 26-member advisory board was appointed in June 1998 and is meeting regularly. The board reports to the Health Ministry and is chaired by the first ministry advisor. Board members include representatives of other ministries, the UNAIDS-funded manager of the initiative, the non-profit company manager, HIV/AIDS researchers, and NGOs representing persons living with HIV. The board is assisted by a technical secretariat, who prepares the technical issues prior to discussions in the board meetings. 20

/ 24

Actions

file_download Download Options Download this page PDF - Pages 1-24 Image - Page 20 Plain Text - Page 20

About this Item

Title
UNAIDS HIV Drug Access Initiative: Providing Wider Access to HIV-related Drugs in Developing Countries, Pilot Phase
Author
Joint United Nations Programme on HIV/AIDS
Canvas
Page 20
Publication
1999-08
Subject terms
reports
Item type:
reports

Technical Details

Link to this Item
https://name.umdl.umich.edu/5571095.0368.003
Link to this scan
https://quod.lib.umich.edu/c/cohenaids/5571095.0368.003/20

Rights and Permissions

The University of Michigan Library provides access to these materials for educational and research purposes, with permission from their copyright holder(s). If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission.

Manifest
https://quod.lib.umich.edu/cgi/t/text/api/manifest/cohenaids:5571095.0368.003

Cite this Item

Full citation
"UNAIDS HIV Drug Access Initiative: Providing Wider Access to HIV-related Drugs in Developing Countries, Pilot Phase." In the digital collection Jon Cohen AIDS Research Collection. https://name.umdl.umich.edu/5571095.0368.003. University of Michigan Library Digital Collections. Accessed May 16, 2025.
Do you have questions about this content? Need to report a problem? Please contact us.